Trial Profile
Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Lipoid nephrosis; Nephrotic syndrome
- Focus Therapeutic Use
- 28 Jul 2020 Status changed from recruiting to discontinued.
- 31 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 26 Mar 2015 New trial record